NOVEMBER 7, 2019

2019 Publication Mixtape

Here is a selection of recent collaborative publications involving DF/HCC authors.

November 2019

Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery.
Sci Rep. 2019 Nov 1. 
Kunjachan S, Kotb S, Pola R, Pechar M, Kumar R, Singh B, Gremse F, Taleeli R, Trichard F, Motto-Ros V, Sancey L, Detappe A, Yasmin-Karim S, Protti A, Shanmugam I, Ireland T, Etrych T, Sridhar S, Tillement O, Makrigiorgos M (DFCI), Berbeco RI (BWH)
PMID: 31676822

October 2019

Immunity to commensal papillomaviruses protects against skin cancer.
Nature. 2019 Oct 30. 
Strickley JD, Messerschmidt JL, Awad ME, Li T, Hasegawa T, Ha DT, Nabeta HW, Bevins PA, Ngo KH, Asgari MM (MGH), Nazarian RM (MGH), Neel VA, Jenson AB, Joh J, Demehri S (MGH)
PMID: 31666702

Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.
N Engl J Med. 2019 Oct 30. 
DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT (MGH), Chen YB (MGH), Hohmann EL. 
PMID: 31665575

Inducible histone K-to-M mutations are dynamic tools to probe the physiological role of site-specific histone methylation in vitro and in vivo.
Nat Cell Biol. 2019 Oct 28. 
Brumbaugh J, Kim IS, Ji F, Huebner AJ, Di Stefano B, Schwarz BA, Charlton J, Coffey A, Choi J, Walsh RM, Schindler JW, Anselmo A, Meissner A, Sadreyev RI, Bernstein BE (MGH), Hock H (MGH), Hochedlinger K (MGH).
PMID: 31659274

Fibroblastic reticular cells enhance T cell metabolism and survival via epigenetic remodeling.
Nat Immunol. 2019 Oct 21.
Brown FD, Sen DR, LaFleur MW, Godec J, Lukacs-Kornek V, Schildberg FA, Kim HJ, Yates KB, Ricoult SJH, Bi K, Trombley JD, Kapoor VN, Stanley IA, Cremasco V, Danial NN (DFCI), Manning BD (HSPH), Sharpe AH (HMS), Haining WN, Turley SJ 
PMID: 31636464

Glycoengineering of Chimeric Antigen Receptor (CAR) T-cells to Enforce E-selectin Binding.
J Biol Chem. 2019 Oct 18. 
Mondal N, Silva M, Castano AP, Maus MV (MGH), Sackstein R (BWH)
PMID: 31628196

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med. 2019 Oct 17. 
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS (DFCI), Wolchok JD. 
PMID: 31562797

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
Nature. 2019 Oct 16. 
Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, Shareef SJ, Javed NM, Raut CP, Eschle BK, Gokhale PC, Hornick JL (BWH), Sicinska ET, Demetri GD (DFCI), Bernstein BE (MGH)
PMID: 31666694

Re-programing Chromatin with a  Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Cancer Cell. 2019 Oct 16. 
Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, Wu M, Nocco S, Bonal DM, Nguyen QD, Suva ML (MGH), Bernstein BE (MGH), Alani R, Golub TR (DFCI), Cole PA (BWH), Filbin MG (DFCI), Shi Y (HMS)
PMID: 31631026

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
J Clin Oncol. 2019 Oct 14. 
Armand P (DFCI), Rodig S (BWH), Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH,  Ouyang J, Neuberg D (DFCI), Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M (DFCI), Zinzani PL. 
PMID: 31609651

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. 
Cancer Cell. 2019 Oct 14. 
Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS (DFCI), Biran A, Fernandes SM, Brown JR (DFCI), Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG (DFCI), Neuberg D (DFCI), Harper JW (HMS), Carr SA, Piccioni F, Ott CJ (MGH), Leshchiner I, Johannessen CM, Doench J, Mootha VK (MGH), Getz G (MGH), Wu CJ (DFCI). 
PMID: 31543463

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
JAMA Oncol. 2019 Oct 10. 
Liu JF (DFCI), Herold C (DFCI)
, Gray KP, Penson RT (MGH), Horowitz N (BWH), Konstantinopoulos PA (DFCI), Castro CM (MGH), Hill SJ, Curtis J, Luo W, Matulonis UA (DFCI), Cannistra SA (BIDMC), Dizon DS. 
PMID: 31600397

Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.
Nature. 2019 Oct 3.
Park E, Rawson S, Li K, Kim BW, Ficarro SB, Pino GG, Sharif H, Marto JA (DFCI), Jeon H, Eck MJ (DFCI). 
PMID: 31581174

PTPN2 regulates the generation of exhausted CD8(+) T cell subpopulations and restrains tumor immunity.
Nat Immunol. 2019 Oct.
LaFleur MW, Nguyen TH, Coxe MA, Miller BC, Yates KB, Gillis JE, Sen DR, Gaudiano EF, Al Abosy R,Freeman GJ (DFCI), Haining WN (DFCI), Sharpe AH (HMS). 
PMID: 31527834

Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging.
Nat Protoc. 2019 Oct.
Du Z, Lin JR, Rashid R, Maliga Z, Wang S, Aster JC (BWH), Izar B, Sorger PK (HMS), Santagata S (BWH). 
PMID: 31534232

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Cell Rep. 2019 Oct 1. 
Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS (DFCI), Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman JHahn WC (DFCI), Aguirre AJ. 
PMID: 31577942

HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Sci Signal. 2019 Oct 1.
Nicholson HE, Tariq Z, Housden BE, Jennings RB, Stransky LA, Perrimon N (HMS), Signoretti S (BWH), Kaelin WG Jr (DFCI)
PMID: 31575731

Hide

September 2019

Performance of breast cancer risk assessment models in a large mammography cohort.
J Natl Cancer Inst.  2019 Sep 26.
McCarthy AM (MGH), Guan Z, Welch M, Griffin ME, Sippo DA, Deng Z, Coopey SB, Acar A, Semine A, Parmigiani G (DFCI), Braun D, Hughes KS (MGH). 
PMID: 31556450

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.
Nat Commun. 2019 Sep 25 
Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, DʼAmico AV (BWH), Kantoff PW, Bradner JE, Mucci LA (HSPH), Chavarro JE (BWH), Loda M, Brown M (DFCI)
PMID: 31554818

Metabolomic adaptations and correlates of survival to immune checkpoint blockade.
Nat Commun. 2019 Sep 25. 
Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S (BWH), McDermott DF (BIDMC), Freeman GJ (DFCI), Van Allen EM (DFCI), Schreiber SL, Stephen Hodi F (DFCI), Sellers WR (DFCI), Garraway LA, Clish CB, Choueiri TK (DFCI), Giannakis M. 
PMID: 31554815

Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.
PLoS One. 2019 Sep 20. 
Lietz AP, Weaver DT, Melamed A, Rauh-Hain JA, Wright JD, Wright AA (DFCI), Knudsen AB, Pandharipande PV (MGH).
PMID: 31539415

A mitotic CDK5-PP4 phospho-signaling cascade primes 53BP1 for DNA repair in G1.
Nat Commun. 2019 Sep 18. 
Zheng XF, Acharya SS, Choe KN, Nikhil K, Adelmant G, Satapathy SR, Sharma S, Viccaro K, Rana S, Natarajan A, Sicinski P (DFCI), Marto JA (DFCI), Shah K, Chowdhury D (DFCI)
PMID: 31534152

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis.
PLoS One. 2019 Sep 17. 
Nelson DS, Marano RL, Joo Y, Tian SY, Patel B, Kaplan DH, Shlomchik MJ, Stevenson K, Bronson RT (HMS), Rollins BJ (DFCI)
PMID: 31527903

Glioblastoma-Associated Microglia Reprogramming Is Mediated by Functional Transfer of Extracellular miR-21.
Cell Rep. 2019 Sep 17.
Abels ER, Maas SLN, Nieland L, Wei Z, Cheah PS, Tai E, Kolsteeg CJ, Dusoswa SA, Ting DT, Hickman S, El Khoury J, Krichevsky AM (BWH), Broekman MLD, Breakefield XO (MGH).
PMID: 31533034

Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.
Nat Commun. 2019 Sep 13
Ding L, Su Y, Fassl A, Hinohara K, Qiu X, Harper NW, Huh SJ, Bloushtain-Qimron N, Jovanović B, Ekram M, Zi X, Hines WC, Alečković M, Gil Del Alcazar C, Caulfield RJ, Bonal DM, Nguyen QD, Merino VF, Choudhury S, Ethington G, Panos L, Grant M, Herlihy W, Au A, Rosson GD, Argani P, Richardson AL, Dillon D, Allred DC, Babski K, Kim EMH, McDonnell CH 3rd, Wagner J, Rowberry R, Bobolis K, Kleer CG, Hwang ES, Blum JL, Cristea S, Sicinski P (DFCI), Fan R, Long HW, Sukumar S, Park SY, Garber JE (DFCI), Bissell M, Yao J, Polyak K (DFCI)
PMID: 31519911

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
J Clin Oncol. 2019 Sep 9. 
Regan MM (DFCI), Werner L, Rao S, Gupte-Singh K, Hodi FS (DFCI), Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF (BIDMC).
PMID: 31498030

Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation.
Nature. 2019 Sep 5. 
Niu J, Sun Y, Chen B, Zheng B, Jarugumilli GK, Walker SR, Hata AN (MGH), Mino-Kenudson M (MGH), Frank DA (DFCI), Wu X (MGH).
PMID: 31462771

Hide

August 2019

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
J Clin Oncol. 2019 Aug 28.
Konstantinopoulos PA (DFCI), Luo W, Liu JF (DFCI), Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB (MGH), Crowe H, Campos S (DFCI), Lindeman NI (BWH), Hill S, Stover E, Schumer S, Wright AA (DFCI), Curtis J, Quinn R, Whalen C, Gray KP, Penson RT (MGH), Cannistra SA (BIDMC), Fleming GF, Matulonis UA (DFCI).
PMID: 31461377

Genomic landscape and chronological reconstruction of driver events in multiple myeloma.
Nat Commun. 2019 Aug 23.
Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, Mitchell TJ, Fullam A, Gonzalez S, Szalat R, Abascal F, Rodriguez-Martin B, Samur MK, Glodzik D, Roncador M, Fulciniti M, Tai YT (DFCI), Minvielle S, Magrangeas F, Moreau P, Corradini P, Anderson KC (DFCI), Tubio JMC, Wedge DC, Gerstung M, Avet-Loiseau H, Munshi N (DFCI), Campbell PJ. 
PMID: 31444325

Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19.
Clin Cancer Res. 2019 Aug 22. 
Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Haaber J, Gjerstorff MF, Ditzel HJ, Weinstock DM (DFCI), Barington T, Frigault MJ, Maus MV (MGH).
PMID: 31439577

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med. 2019 Aug 22.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG (DFCI), Jagannath S. 
PMID: 31433920

The Histone Deacetylase SIRT6 Restrains Transcription Elongation via Promoter-Proximal Pausing.
Mol Cell. 2019 Aug 22.
Etchegaray JP, Zhong L, Li C, Henriques T, Ablondi E, Nakadai T, Van Rechem C, Ferrer C, Ross KN, Choi JE, Samarakkody A, Ji F, Chang A, Sadreyev RI, Ramaswamy S, Nechaev S, Whetstine JR (MGH), Roeder RG, Adelman K, Goren A, Mostoslavsky R (MGH)
PMID: 31399344

Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells.
Nat Commun. 2019 Aug 19. 
Reitman ZJ, Paolella BR, Bergthold G, Pelton K, Becker S, Jones R, Sinai CE, Malkin H, Huang Y, Grimmet L, Herbert ZT, Sun Y, Weatherbee JL, Alberta JA, Daley JF, Rozenblatt-Rosen O, Condurat AL, Qian K, Khadka P, Segal RA (DFCI), Haas-Kogan D (DFCI), Filbin MG (DFCI), Suva ML (MGH), Regev A, Stiles CD (DFCI), Kieran MW (DFCI), Goumnerova L (BCH), Ligon KL (DFCI), Shalek AK, Bandopadhayay P (DFCI), Beroukhim R (DFCI).
PMID: 31427603

Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer.
Cancer Discov. 2019 Aug 15. 
Farago AF (MGH), Yeap BY (MGH), Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D (BIDMC), Barbie DA (DFCI), Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV (MGH), Hata AN (MGH), Maheswaran S (MGH), Haber DA (MGH), Lawrence MS (MGH), Shaw AT (MGH), Mino-Kenudson M (MGH), Dyson NJ (MGH) Drapkin BJ.
PMID: 31416802

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.
Sci Transl Med. 2019 Aug 14. 
Chiocca EA (BWH), Yu JS, Lukas RV, Solomon IH, Ligon KL (DFCI), Nakashima H, Triggs DA, Reardon DA (DFCI), Wen P (DFCI), Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN.
PMID: 31413142

LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression.
Oncogene. 2019 Aug 13. 
Hu X, Xiang D, Xie Y, Tao L, Zhang Y, Jin Y, Pinello L, Wan Y, Yuan GC (DFCI), Li Z (BWH).  
PMID: 31409898

Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer.
Nat Genet. 2019 Aug 12.
Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, Rosenfeld JA, Cox AG, Hedgepeth J, Wucherpfennig JI, Kim AJ, Henderson JE, Gonyo  P, Brandt A, Lorimer E, Unger B, Prokop JW, Heidel JR, Wang XX, Ukaegbu CI, Jennings BC, Paulo JA, Gableske S, Fierke CA, Getz G (MGH), Sunyaev SR, Wade Harper J (HMS) Cichowski K (BWH), Kimmelman AC, Houvras Y, Syngal S (DFCI), Williams C, Goessling W (MGH)
PMID: 31406347

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Science. 2019 Aug 9. 
Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D (DFCI), Lindsley RC (DFCI), Jänne PA (DFCI), Hahn WC (DFCI), Jacks T, Döhner H, Armstrong SA (DFCI), Ebert BL (DFCI).
PMID: 31395785

T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes.
Cell. 2019 Aug 8. 
Kula T, Dezfulian MH, Wang CI, Abdelfattah NS, Hartman ZC, Wucherpfennig KW (DFCI), Lyerly HK, Elledge SJ (BWH).
PMID: 31398327

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
Cell. 2019 Aug 8. 
Neftel C, Laffy J, Filbin MG (DFCI), Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV (MGH), Curry WT (MGH), Carter BS (MGH), Wakimoto H (MGH), Brastianos PK (MGH), Batchelor TT (MGH), Stemmer-Rachamimov A (MGH), Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP (MGH), Patel AP, Hunter T, Verma IM, Ligon KL (DFCI), Louis DN (MGH), Regev A, Bernstein BE (MGH), Tirosh I, Suvà ML (MGH).
PMID: 31327527

BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
Nature. 2019 Aug 7. 
Debruyne DN, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, Huang H, Moreau L, McLane M, Day DS, Marco E, Chen T, Gray NS (DFCI), Wong KK, Orkin SH (DFCI), Yuan GC (DFCI), Young  RA, George RE (DFCI)
PMID: 31391581

Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Cell Rep. 2019 Aug 6. 
Johnson CW, Lin YJ, Reid D, Parker J, Pavlopoulos S, Dischinger P, Graveel C, Aguirre AJ, Steensma M, Haigis KM (BIDMC), Mattos C.
PMID: 31390567

Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding.
Science. 2019 Aug 2. 
Twomey EC, Ji Z, Wales TE, Bodnar NO, Ficarro SB, Marto JA (DFCI), Engen JR, Rapoport TA (HMS).
PMID: 31249135

Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.
Oncogene. 2019 Aug 1.
Ou WB, Ni N, Zuo R, Zhuang W, Zhu M, Kyriazoglou A, Wu D, Eilers G, Demetri GD (DFCI), Qiu H, Li B, Marino-Enriquez A, Fletcher JA (BWH).  
PMID: 31371779

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.
Nat Med. 2019 Aug 1. 
Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V (MGH), Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC (MGH), Bernstein BE (MGH), Shivdasani RA (DFCI).
PMID: 31263286

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Lancet Haematol. 2019 Aug 1.
Davids MS (DFCI), Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P (DFCI), Ng  S, Crombie J, LaCasce AS (DFCI), Arnason J, Hochberg EP (MGH), Takvorian RW (MGH), Abramson JS (MGH), Fisher DC (DFCI), Brown JR (DFCI); Blood Cancer Research Partnership of the Leukemia & Lymphoma Society. 
PMID: 31208944

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Cancer Discov. 2019 Aug 1.
Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR (MGH), Tanabe KK (MGH), Deshpande V (MGH), Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ (MGH), Hahn WC (DFCI), Benes CH, Ting DT (MGH), Hirai H, Getz G (MGH), Juric D, Zhu AX (MGH), Corcoran RB (MGH), Bardeesy N (MGH).
PMID: 31109923

Resolving medulloblastoma cellular architecture by single-cell genomics.
Nature. 2019 Aug 1. 
Hovestadt V, Smith KS, Bihannic L, Filbin MG, Shaw ML, Baumgartner A, DeWitt JC, Groves A, Mayr L, Weisman HR, Richman AR, Shore ME, Goumnerova L, Rosencrance C, Carter RA, Phoenix TN, Hadley JL, Tong Y, Houston J, Ashmun RA, DeCuypere M, Sharma T, Flasch D, Silkov A, Ligon KL (DFCI), Pomeroy SL (BCH), Rivera MN, Rozenblatt-Rosen O, Rusert JM, Wechsler-Reya RJ, Li XN, Peyrl A, Gojo J, Kirchhofer D, Lötsch D, Czech T, Dorfer C, Haberler C, Geyeregger R, Halfmann A, Gawad C, Easton J, Pfister SM, Regev A, Gajjar A, Orr BA, Slavc I, Robinson GW, Bernstein BE (MGH), Suvà ML (MGH), Northcott PA.
PMID: 31341285

Hide